RFI_Cover_Letter_HQ0034-17-R-0035_eud.pdf

HQ0034-17-R-0037

Request for Synthetic Cannabinoids Immunoassay Reagent Support for the Department of Defense

(DoD) Drug Demand Reduction Program (DDRP)

RFI Date: January 5, 2017

Due Date: January 19, 2017

Synopsis of RFI:

The Department of Defense (DoD) Drug Demand Reduction Program (DDRP) is seeking input from business sources for its Synthetic Cannabinoids Immunoassay Reagent requirement.

The immunoassay reagent must be adaptable without modification to the existing Beckman Coulter AU5800 series clinical chemistry analyzer systems employed at the DoD Drug Testing Laboratories (FTDTLs) and Division of Forensic Toxicology (FORTOX), Armed Forces Medical Examiner System (AFMES). DDRP will not sponsor companies for this requirement.

Attachments:

1. Performance Work Statement (PWS)

Questions regarding this solicitation should be sent to Peggie Lowery and Eric Darby no later than 11:00 A.M. ET on Thursday, January 19, 2017 @ peggie.l.lowery2.civ@mail.mil and eric.u.darby.civ@mail.mil.

Department of Defense Drug Demand Reduction Program (DDRP) RFI – Synthetic Cannabinoids Immunoassay Testing Reagent

The Department of Defense (DoD) Drug Demand Reduction Program (DDRP) is seeking input from business sources for its Synthetic Cannabinoids Immunoassay Testing Reagent requirement.

This is not a solicitation announcement. This notice neither constitutes a Request for Proposal, nor does it restrict the Washington Headquarters Services, Acquisition Directorate (WHS/AD) to the ultimate acquisition approach. No contract will be awarded from this announcement and requests for solicitation will not receive a response. No reimbursement will be made for any cost associated with providing information in response to this announcement. Any information submitted by respondents is strictly voluntary.

These exchanges are in support of market research being conducted by WHS/AD to determine if there are businesses in the market that provide this service and the adequacy of the PWS. This includes its clarification of contract requirements, completeness of the PWS, examination of performance metric for realism, and contract type.

The immunoassay reagent must be adaptable without modification to the existing Beckman Coulter AU5800 series clinical chemistry analyzer systems employed at the DoD Drug Testing Laboratories (FTDTLs) and Division of Forensic Toxicology (FORTOX), Armed Forces Medical Examiner System (AFMES).

Specifically, WHS/AD would like information and comments on the following:

1. A brief two or three page synopsis of similar work performed in the past supplying immunoassay reagent to detect synthetic cannabinoids, both parent and/or metabolites, in urine resulting from synthetic cannabinoid (aka ‘Spice’) use.

2. The adequacy of the information in the PWS and RFI.

3. Validation of applicable NAICS Code for this requirement.

a. 424210 – Drugs and Druggists' Sundries Merchant Wholesalers

4. Industry partners with whom you could team to meet the requirement.

5. Your interest in bidding on the requirement.

6. If there are any other questions or comments, please submit them along with your response.

If there are any questions regarding this notice, they should be directed to Peggie Lowery at peggie.l.lowery2.civ@mail.mil or 703-545-9511 and Eric Darby at eric.u.darby.civ@mail.mil.

All responses to this RFI shall be submitted no later than 11:00AM ET, Thursday, January 19, 2017. Please limit your response to no more than five (5) pages (excluding questions), using Time New Roman 12 pt. font or equivalent. WHS/AD may have one-on-one sessions (telephonically) with respondents after feedback has been received.

Department of Defense Drug Demand Reduction Program (DDRP) RFI – Synthetic Cannabinoids Immunoassay Testing Reagent

Additional Information

Contracting Office Address:

WHS/AD, 1225 South Clark Street, Suite 1202, Arlington, VA 22202

Place of Performance: Contractor Site

Anticipated Period of Performance:

Base: May 2017 – May 2018

Option 1: May 2018 – May 2019

Option 2: May 2019 – May 2020

Option 3: May 2020 – May 2021

Option 4: May 2021 – May 2022

Incumbent:

Immunalysis Corporation is the incumbent on this requirement. The contract number HQ0034- 13-D-0005.